The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcγ receptors

Omalizumab is an anti-IgE monoclonal antibody (mAb) approved for the treatment of severe asthma and chronic spontaneous urticaria. Use of omalizumab is associated with reported side effects ranging from local skin inflammation at the injection site to systemic anaphylaxis. To date, the mechanisms th...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Invest
Autors principals: Balbino, Bianca, Herviou, Pauline, Godon, Ophélie, Stackowicz, Julien, Goff, Odile Richard-Le, Iannascoli, Bruno, Sterlin, Delphine, Brûlé, Sébastien, Millot, Gael A., Harris, Faith M., Voronina, Vera A., Nadeau, Kari C., Macdonald, Lynn E., Murphy, Andrew J., Bruhns, Pierre, Reber, Laurent L.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2020
Matèries:
Concise Communication
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7269578/
https://ncbi.nlm.nih.gov/pubmed/31770111
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI129697
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars